Alcoholic Liver Disease/Nonalcoholic Fatty Liver Disease Index for Classification of Patients with Steatotic Liver Disease

被引:1
|
作者
Roy, Akash [1 ]
De, Arka [2 ]
Kulkarni, Anand V. [3 ]
Jajodia, Surabhi [4 ]
Goenka, Usha [4 ]
Tewari, Awanish [1 ]
Sonthalia, Nikhil [1 ]
Goenka, Mahesh K. [1 ]
机构
[1] Apollo Multispecial Hosp, Inst Gastrosci & Liver Transplantat, Kolkata, India
[2] Post Grad Inst Med Educ & Res, Dept Hepatol, Chandigarh, India
[3] Asian Inst Gastroenterol, Dept Hepatol, Hyderabad, India
[4] Apollo Multispecial Hosp, Dept Radiol & Imaging, Kolkata, India
关键词
Non-alcoholic fatty liver disease; Liver steatosis; Alcoholic fatty liver; GAMMA-GLUTAMYL-TRANSFERASE;
D O I
10.7570/jomes23063
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Steatotic liver disease (SLD) encompasses metabolic dysfunction-associated steatotic liver disease (MASLD) and alcohol-associated liver disease (AALD) at extremes as well as an overlap group termed MASLD with increased alcohol intake (MetALD). The Alcoholic Liver Disease/Nonalcoholic Fatty Liver Disease Index (ANI) was proposed to differentiate ALD from nonalcoholic fatty liver disease (NAFLD). We analysed the performance of the ANI in differentiating within the SLD spectrum. Methods: In a cross-sectional study at a tertiary care center, 202 adults (>18 years) who were prospectively diagnosed with SLD defined by magnetic resonance imaging-proton density fat fraction > 6.4% were enrolled. Alcohol consumption (AC) was recorded according to thresholds for significant AC: 140-350 g/week (or 20- 50 g/day) for females and 210-420 g/week (or 30-60 g/day) for males. The ANI was calculated, and area under the receiver operating characteristic curve (AUROC) was generated. Results: Of 202 patients (47 years [interquartile range, IQR, 38 to 55], 23.75% females, 77% obese, 42.1% with diabetes, 38.1% hypertensive, 28.7% statin use), 40.5% were ever-alcohol consumers; 120 (59%), 50 (24.7%), and 32 (15.8%) were MASLD (ANI, -3.7 [IQR, -7 to -1.6]; MetALD, - 1.45 [IQR, -2.4 to 0.28]; and AALD, 0.71 [IQR, -1.3 to 4.8], respectively; P< 0.05 for all). The AUROC of the ANI for MASLD and AALD was 0.79 (IQR, 0.72 to 0.84; cut-off < -3.5) and 0.80 (IQR, 0.74 to 0.86; cut-off > -1.49), respectively. The ANI outperformed aspartate transaminase/alanine transaminase (AST/ALT) ratio (AUROC=0.75 [IQR, 0.69 to 0.81]) and gamma glutamyl transpeptidase (GGT) (AUROC=0.74 [IQR, 0.67 to 0.80]). Addition of GGT did not improve model performance (AUCdiff=0.004; P= 0.33). Conclusion: AC is common in MASLD. The ANI distinguishes MASLD and AALD, with individual cut-offs within the intermediate zone indicating MetALD. ANI also outperforms AST/ALT ratio or GGT.
引用
收藏
页码:222 / 228
页数:7
相关论文
共 50 条
  • [1] Alcoholic liver disease/nonalcoholic fatty liver disease index: distinguishing alcoholic from nonalcoholic fatty liver disease
    Cerovic, Ivana
    Mladenovic, Dusan
    Jesic, Rada
    Naumovic, Tamara
    Brankovic, Milos
    Vucevic, Danijela
    Aleksic, Vuk
    Radosavljevic, Tatjana
    EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 2013, 25 (08) : 899 - 904
  • [2] THE ALCOHOLIC LIVER DISEASE/ NONALCOHOLIC FATTY LIVER DISEASE INDEX ( ANI) IN CLASSIFICATION OF PATIENTS WITH METABOLIC DYSFUNCTION ASSOCIATED FATTY LIVER DISEASE ( MAFLD)
    Roy, Akash
    Goenka, Usha
    Jajodia, Surabhi
    Tewari, Awanish
    Verma, Nipun
    Goenka, Mahesh
    HEPATOLOGY, 2023, 78 : S884 - S885
  • [3] Genetics of alcoholic liver disease and nonalcoholic fatty liver disease
    de Alwis, Nimantha Mark Wilfred
    Day, Christopher Paul
    SEMINARS IN LIVER DISEASE, 2007, 27 (01) : 44 - 54
  • [4] Impact of body mass index in liver transplantation for nonalcoholic fatty liver disease and alcoholic liver disease
    O'Neill, Stephen
    Napetti, Sara
    Cornateanu, Sorina
    Sutherland, Andrew I.
    Wigmore, Stephen
    Oniscu, Gabriel C.
    Adair, Anya
    HPB, 2017, 19 (12) : 1074 - 1081
  • [5] Probiotics in treating with alcoholic liver disease and nonalcoholic fatty liver disease
    Liu, Lingchong
    Wang, Yu
    Zhang, Jing
    Wang, Chao
    Li, Youbao
    Dai, Weichang
    Piao, Chunhong
    Liu, Junmei
    Yu, Hansong
    Li, Xia
    Wang, Yuhua
    Liu, Jingsheng
    FOOD REVIEWS INTERNATIONAL, 2023, 39 (05) : 2723 - 2741
  • [6] Nonalcoholic fatty liver disease: Implications for alcoholic liver disease pathogenesis
    Diehl, AM
    ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH, 2001, 25 (05) : 8S - 14S
  • [7] Pathogenesis and pathways: nonalcoholic fatty liver disease & alcoholic liver disease
    Robinson, Kyle E.
    Shah, Vijay H.
    TRANSLATIONAL GASTROENTEROLOGY AND HEPATOLOGY, 2020, 5
  • [8] Is nonalcoholic fatty liver disease an endogenous alcoholic fatty liver disease? - A mechanistic hypothesis
    de Medeiros, Ivanildo Coutinho
    de Lima, Josivan Gomes
    MEDICAL HYPOTHESES, 2015, 85 (02) : 148 - 152
  • [9] Comparative redox status in alcoholic liver disease and nonalcoholic fatty liver disease
    Payal Bhardwaj
    Kaushal Madan
    Sandeep Thareja
    Yogendra Kumar Joshi
    Anoop Saraya
    Hepatology International, 2008, 2 : 202 - 208
  • [10] Clinical differences between alcoholic liver disease and nonalcoholic fatty liver disease
    Toshikuni, Nobuyuki
    Tsutsumi, Mikihiro
    Arisawa, Tomiyasu
    WORLD JOURNAL OF GASTROENTEROLOGY, 2014, 20 (26) : 8393 - 8406